{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T15:57:55Z","timestamp":1792252675580,"version":"4.4.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100010795","name":"Chugai Pharmaceutical Co., Ltd.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100010795","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s40120-025-00799-7","type":"journal-article","created":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T23:03:35Z","timestamp":1758841415000},"page":"2429-2451","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Safety and Effectiveness of Satralizumab in Japanese Patients with Neuromyelitis Optica Spectrum Disorder: A 30\u2011Month Interim Analysis of Post\u2011marketing Surveillance"],"prefix":"10.1007","volume":"14","clinical-trial-number":[{"clinical-trial-number":"umin000041047","registry":"10.18810\/umin-japan"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9048-0375","authenticated-orcid":false,"given":"Takashi","family":"Yamamura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9525-4254","authenticated-orcid":false,"given":"Noriko","family":"Isobe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7140-8500","authenticated-orcid":false,"given":"Izumi","family":"Kawachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiyoko","family":"Nohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8235-7569","authenticated-orcid":false,"given":"Yusei","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3201-305X","authenticated-orcid":false,"given":"Minami","family":"Tomita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3220-0084","authenticated-orcid":false,"given":"Yuta","family":"Kamei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5761-1609","authenticated-orcid":false,"given":"Katsuhisa","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5858-0998","authenticated-orcid":false,"given":"Jin","family":"Nakahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2612-8948","authenticated-orcid":false,"given":"Ichiro","family":"Nakashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3096-4156","authenticated-orcid":false,"given":"Kazuo","family":"Fujihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,26]]},"reference":[{"key":"799_CR1","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1097\/ICU.0000000000000703","volume":"31","author":"KB Holroyd","year":"2020","unstructured":"Holroyd KB, Manzano GS, Levy M. Update on neuromyelitis optica spectrum disorder. Curr Opin Ophthalmol. 2020;31:462\u20138.","journal-title":"Curr Opin Ophthalmol"},{"key":"799_CR2","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","volume":"85","author":"DM Wingerchuk","year":"2015","unstructured":"Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85:177\u201389.","journal-title":"Neurology"},{"key":"799_CR3","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1055\/s-0043-1761432","volume":"81","author":"RB Paolilo","year":"2023","unstructured":"Paolilo RB, da Paz JA, Ap\u00f3stolos-Pereira SL, Rimkus CDM, Callegaro D, Sato DK. Neuromyelitis optica spectrum disorders: a review with a focus on children and adolescents. Arq Neuropsiquiatr. 2023;81:201\u201311.","journal-title":"Arq Neuropsiquiatr"},{"key":"799_CR4","doi-asserted-by":"publisher","first-page":"e209992","DOI":"10.1212\/WNL.0000000000209992","volume":"103","author":"M Watanabe","year":"2024","unstructured":"Watanabe M, Isobe N, Niino M, Nakashima I, Matsushita T, Sakai Y, et al. Prevalence of, and disability due to, multiple sclerosis and neuromyelitis optica spectrum disorder in Japan by the fifth nationwide survey. Neurology. 2024;103:e209992.","journal-title":"Neurology"},{"key":"799_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102522","volume":"46","author":"X Ma","year":"2020","unstructured":"Ma X, Kermode AG, Hu X, Qiu W. Risk of relapse in patients with neuromyelitis optica spectrum disorder: recognition and preventive strategy. Mult Scler Relat Disord. 2020;46:102522.","journal-title":"Mult Scler Relat Disord"},{"key":"799_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2024.105829","volume":"90","author":"M Niino","year":"2024","unstructured":"Niino M, Isobe N, Araki M, Ohashi T, Okamoto T, Ogino M, et al. Clinical practice guidelines for multiple sclerosis, neuromyelitis optica spectrum disorder, and myelin oligodendrocyte glycoprotein antibody-associated disease 2023 in Japan. Mult Scler Relat Disord. 2024;90:105829.","journal-title":"Mult Scler Relat Disord"},{"key":"799_CR7","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.cca.2013.03.020","volume":"421","author":"A Uzawa","year":"2013","unstructured":"Uzawa A, Mori M, Sawai S, Masuda S, Muto M, Uchida T, et al. Cerebrospinal fluid interleukin-6 and glial fibrillary acidic protein levels are increased during initial neuromyelitis optica attacks. Clin Chim Acta. 2013;421:181\u20133.","journal-title":"Clin Chim Acta"},{"key":"799_CR8","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1136\/jnnp-2018-317969","volume":"89","author":"K Kaneko","year":"2018","unstructured":"Kaneko K, Sato DK, Nakashima I, Ogawa R, Akaishi T, Takai Y, et al. CSF cytokine profile in MOG-IgG+ neurological disease is similar to AQP4-IgG+ NMOSD but distinct from MS: a cross-sectional study and potential therapeutic implications. J Neurol Neurosurg Psychiatry. 2018;89:927\u201336.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"799_CR9","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1080\/14737175.2020.1757434","volume":"20","author":"M Rosso","year":"2020","unstructured":"Rosso M, Saxena S, Chitnis T. Targeting IL-6 receptor in the treatment of neuromyelitis optica spectrum: a review of emerging treatment options. Expert Rev Neurother. 2020;20:509\u201316.","journal-title":"Expert Rev Neurother"},{"key":"799_CR10","doi-asserted-by":"publisher","first-page":"2801","DOI":"10.3390\/ijms22062801","volume":"22","author":"M Waliszewska-Pros\u00f3\u0142","year":"2021","unstructured":"Waliszewska-Pros\u00f3\u0142 M, Chojdak-\u0141ukasiewicz J, Budrewicz S, Pokryszko-Dragan A. Neuromyelitis optica spectrum disorder treatment\u2014current and future prospects. Int J Mol Sci. 2021;22:2801.","journal-title":"Int J Mol Sci"},{"key":"799_CR11","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/S1474-4422(20)30078-8","volume":"19","author":"A Traboulsee","year":"2020","unstructured":"Traboulsee A, Greenberg BM, Bennett JL, Szczechowski L, Fox E, Shkrobot S, et al. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. Lancet Neurol. 2020;19:402\u201312.","journal-title":"Lancet Neurol"},{"key":"799_CR12","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1056\/NEJMoa1901747","volume":"381","author":"T Yamamura","year":"2019","unstructured":"Yamamura T, Kleiter I, Fujihara K, Palace J, Greenberg B, Zakrzewska-Pniewska B, et al. Trial of satralizumab in neuromyelitis optica spectrum disorder. N Engl J Med. 2019;381:2114\u201324.","journal-title":"N Engl J Med"},{"key":"799_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.104025","volume":"66","author":"T Yamamura","year":"2022","unstructured":"Yamamura T, Weinshenker B, Yeaman MR, De Seze J, Patti F, Lobo P, et al. Long-term safety of satralizumab in neuromyelitis optica spectrum disorder (NMOSD) from SAkuraSky and SAkuraStar. Mult Scler Relat Disord. 2022;66:104025.","journal-title":"Mult Scler Relat Disord"},{"key":"799_CR14","unstructured":"Chugai. Chugai\u2019s Enspryng (satralizumab) subcutaneous injection 120 mg syringe approved in Japan for neuromyelitis optica spectrum disorder. Chugai news release. 2020 [cited 2024 Nov 4]. https:\/\/www.chugai-pharm.co.jp\/english\/news\/detail\/20200629170000_738.html."},{"key":"799_CR15","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1007\/s40265-020-01380-2","volume":"80","author":"Y-A Heo","year":"2020","unstructured":"Heo Y-A. Satralizumab: first approval. Drugs. 2020;80:1477\u201382.","journal-title":"Drugs"},{"key":"799_CR16","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1007\/s40120-024-00640-7","volume":"13","author":"T Yamamura","year":"2024","unstructured":"Yamamura T, Isobe N, Kawachi I, Nohara C, Miyazaki Y, Tomita M, et al. Safety and effectiveness of satralizumab in Japanese patients with neuromyelitis optica spectrum disorder: a 6-month interim analysis of post-marketing surveillance. Neurol Ther. 2024;13:1361\u201383.","journal-title":"Neurol Ther"},{"key":"799_CR17","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1007\/s13311-021-01055-0","volume":"18","author":"L Cacciaguerra","year":"2021","unstructured":"Cacciaguerra L, Tortorella P, Rocca MA, Filippi M. Targeting neuromyelitis optica pathogenesis: results from randomized controlled trials of biologics. Neurotherapeutics. 2021;18:1623\u201336.","journal-title":"Neurotherapeutics"},{"key":"799_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2025.106444","volume":"99","author":"BM Greenberg","year":"2025","unstructured":"Greenberg BM, Fujihara K, Weinshenker B, Patti F, Kleiter I, Bennett JL, et al. Analysis of infection rates in neuromyelitis optica spectrum disorder: comparing satralizumab treatment in SAkuraMoon, post-marketing, and US-based health claims data. Mult Scler Relat Disord. 2025;99:106444.","journal-title":"Mult Scler Relat Disord"},{"key":"799_CR19","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.3899\/jrheum.141210","volume":"42","author":"K Yamamoto","year":"2015","unstructured":"Yamamoto K, Goto H, Hirao K, Nakajima A, Origasa H, Tanaka K, et al. Longterm safety of tocilizumab: results from 3 years of followup postmarketing surveillance of 5573 patients with rheumatoid arthritis in Japan. J Rheumatol. 2015;42:1368\u201375.","journal-title":"J Rheumatol"},{"key":"799_CR20","doi-asserted-by":"publisher","first-page":"185","DOI":"10.5213\/inj.1836050.025","volume":"22","author":"A Declemy","year":"2018","unstructured":"Declemy A, Chesnel C, Charlanes A, Le Breton F, Ismael SS, Amarenco G. Specificity of lower urinary tract symptoms in neuromyelitis optica in comparison with multiple sclerosis patients. Int Neurourol J. 2018;22:185\u201391.","journal-title":"Int Neurourol J"},{"key":"799_CR21","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S1474-4422(24)00514-3","volume":"24","author":"AA Habib","year":"2025","unstructured":"Habib AA, Zhao C, Aban I, Fran\u00e7a MC, Jos\u00e9 JG, zu H\u00f6rste GM, et al. Safety and efficacy of satralizumab in patients with generalised myasthenia gravis (LUMINESCE): a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. Lancet Neurol. 2025;24:117\u201327.","journal-title":"Lancet Neurol"},{"key":"799_CR22","doi-asserted-by":"publisher","first-page":"129","DOI":"10.7224\/1537-2073.2017-076","volume":"21","author":"MA Mealy","year":"2019","unstructured":"Mealy MA, Boscoe A, Caro J, Levy M. Assessment of patients with neuromyelitis optica spectrum disorder using the EQ-5D. Int J MS Care. 2019;21:129\u201334.","journal-title":"Int J MS Care"},{"key":"799_CR23","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.abd.2023.05.005","volume":"99","author":"LCP Tavares","year":"2024","unstructured":"Tavares LCP, Caetano LDVN, Ianhez M. Side effects of chronic systemic glucocorticoid therapy: what dermatologists should know. An Bras Dermatol. 2024;99:259\u201368.","journal-title":"An Bras Dermatol"},{"key":"799_CR24","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/ncpendmet0791","volume":"4","author":"S Trikudanathan","year":"2008","unstructured":"Trikudanathan S, McMahon GT. Optimum management of glucocorticoid-treated patients. Nat Clin Pract Endocrinol Metab. 2008;4:262\u201371.","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"799_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2024.105502","volume":"84","author":"I Nakashima","year":"2024","unstructured":"Nakashima I, Nakahara J, Yasunaga H, Yamashita M, Nishijima N, Satomura A, et al. Real-world management of patients with neuromyelitis optica spectrum disorder using satralizumab: results from a Japanese claims database. Mult Scler Relat Disord. 2024;84:105502.","journal-title":"Mult Scler Relat Disord"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-025-00799-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-025-00799-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-025-00799-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T10:45:05Z","timestamp":1763376305000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-025-00799-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,26]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["799"],"URL":"https:\/\/doi.org\/10.1007\/s40120-025-00799-7","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,26]]},"assertion":[{"value":"18 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Takashi Yamamura served on scientific advisory boards for Chugai Pharmaceutical, Roche, Biogen Japan, Biogen MA, Novartis Pharma, and Mitsubishi Tanabe Pharma; received research grants from Chugai Pharmaceutical, Novartis Pharma, Biogen Japan, Chiome Bioscience, Sanofi, UCB Japan, and Mebix; received research funding from Alexion G.K.; and received speaker honoraria from Chugai Pharmaceutical, Biogen Japan, Novartis Pharma, Mitsubishi Tanabe Pharma, Takeda Pharmaceuticals, Miyarisan Pharmaceutical, Alexion Pharmaceuticals, Sumitomo Pharma, and Teijin Pharma. Noriko Isobe has received speaker honoraria from Biogen Japan, Novartis Pharma, Alexion Pharmaceuticals, Chugai Pharmaceutical, Daiichi Sankyo, Takeda Pharmaceuticals, Ono Pharmaceutical, Eisai, Otsuka Pharmaceutical, Kyowa Kirin, EA Pharma, FP Pharmaceutical, Mitsubishi Tanabe Pharma, UCB Japan, Japan Blood Product Organization, Argenx, Sanofi, Amgen, and Alnylam. She has also received research grants for her department from Sumitomo Pharma, Chugai Pharmaceutical, Biogen Japan, and Kyowa Kirin. Izumi Kawachi received a grant from JSPS KAKENHI (grant number: 20K07899, JP23K06923) and the MHLW Research Program on Rare and Intractable Diseases, Grant\/Award (JPMH 20FC1030, JPMH 23FC1009); funding for research, travel, and\/or speaker honoraria from Chugai Pharmaceutical, Novartis Pharma, Biogen Japan, Alexion Pharmaceuticals, Mitsubishi Tanabe Pharma, Takeda Pharmaceuticals, Teijin Pharma, Argenx, UCB, and Daiichi Sankyo; and is a scientific advisory board member for Chugai Pharmaceutical and UCB. Chiyoko Nohara received speaker honoraria from Chugai Pharmaceutical, Biogen Japan, Novartis Pharma, Alexion Pharmaceuticals, and Mitsubishi Tanabe Pharma. Yusei Miyazaki received funding for travel and\/or speaker honoraria from Alexion Pharmaceuticals, Biogen Japan, Chugai Pharmaceutical, Daiichi Sankyo, Mitsubishi Tanabe Pharma, Novartis Pharma, Takeda Pharmaceuticals, and Teijin Pharma. Minami Tomita, Yuta Kamei, and Katsuhisa Yamashita are employees of Chugai Pharmaceutical. Jin Nakahara received speaker honoraria from Alexion Pharmaceuticals, Chugai Pharmaceutical, Mitsubishi Tanabe Pharma, and Roche; served as a paid consultant for Alexion Pharmaceuticals, Chugai Pharmaceutical, Horizon, Mitsubishi Tanabe Pharma, and Roche; and received research grants from Chugai Pharmaceutical, Mitsubishi Tanabe Pharma, MEXT, and MHLW. Ichiro Nakashima serves on the scientific advisory boards for Biogen Japan, and Novartis Pharma; and receives honoraria for speaking engagements with Chugai Pharmaceutical, Alexion Pharmaceuticals, Biogen Japan, Mitsubishi Tanabe Pharma, and Novartis Pharma. Ichiro Nakashima is a member of advisory board of Chugai Pharmaceutical and received consultancy and speaker\u2019s bureau fees from Chugai Pharmaceutical. Kazuo Fujihara\u00a0serves as an advisor on the scientific advisory boards for Biogen, Mitsubishi Tanabe Pharma, Novartis Pharma, Chugai Pharmaceutical, Roche, Alexion Pharmaceuticals, Viela Bio\/Horizon Therapeutics, UCB, Merck, Japan Tobacco, and AbbVie; has received funding for travel and speaker honoraria from Biogen, Eisai, Mitsubishi Tanabe Pharma, Novartis Pharma, Chugai Pharmaceutical, Roche, Alexion Pharmaceuticals, Viela Bio, Teijin, Asahi Kasei, Merck, and Takeda Pharmaceuticals; and has received Grants-in-Aid for scientific research from the Ministry of Education, Culture, Sports, Science and Technology of Japan and Grants-in-Aid for scientific research from the Ministry of Health, Labour and Welfare of Japan.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study followed the same ethical considerations as disclosed previously [\n                      \n                      ]. This PMS study is ongoing in compliance with Japanese regulations (Ministerial Ordinance on Good Post-marketing Study Practice for Drugs [GPSP], MHLW Ministerial Ordinance No. 38, March 23, 2005), as is the case with general PMS studies in Japan. The study did not undergo review by the ethics committee of the participating medical institutions or follow procedures for informed consent, as this was not required for PMS studies according to Japanese regulations of the Act on Securing Quality, Efficacy and Safety of Products including Pharmaceuticals and Medical Devices. The study was designed to collect information from physicians in daily medical practice. Therefore, there are no disadvantages for patients because alternative treatments (such as those in the control group), placebo administration, or an increased frequency of hospital visits or tests beyond routine medical care are not being implemented. In addition, patients routinely have the opportunity to request treatment discontinuation or modification.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}